Objective Assessment of Lung Disease

Pharmacotherapy II, January 2020

Ronald Sorkness, PhD University of Wisconsin School of Pharmacy

Objectives

- Understand the physiology of abnormal ventilation and gas exchange
- Be able to recognize abnormalities in ventilation, oxygenation, and acid-base balance from the Arterial Blood Gases report
- Be able to utilize the results of the following Pulmonary Function Tests for assessing and monitoring patients with asthma, COPD, or pulmonary fibrosis: lung volumes, FEV1, FVC, FEV1/FVC, PEF, DLCO, bronchodilator reversibility, bronchoprovocation, 6-min walk

Clinical Uses of Blood Gases

- Most Common:
 - -Ventilation and gas exchange
 - –Acid-base status
- Less Common:
 - Superior vena caval O₂ saturation
 - Oxygen delivery
 - Oxygen consumption/metabolic rate

Abbreviations

- P = partial pressure of gas
- C = concentration or content
- S = HGB %saturation


- a = arterial
- A = alveolar
- I = inspired air
- v = venous
- c = capillary
- $\overline{\mathbf{v}}$ = mixed venous
- $\mathbf{\hat{V}}$ = flow or ventilation rate
- **V/Q = ventilation/perfusion**


Normal Arterial Blood Values


- Measured
 pH 7.36-7.44
 PaO₂ >80 mmHg
 PaCO₂ 34-46 mmHg
- Computed HCO₃ 22-26 mmol/L (or mEq/L) Base Excess -2.5 to +2.5 mmol/L (or mEq/L) SaO₂ >94% (may also be measured directly)

Noninvasive Alternatives

- Pulse Oximetry (SpO₂)- estimate of SaO2 using spectrophotometric measure at nail bed
- Others not used commonly:
 - Transcutaneous electrodes- most useful in thin-skinned neonates
 - Expired gases- end-tidal gas concentrations reflect alveolar gases










Ventilation

PaCO₂ on the Arterial Blood Gases report is an indicator of *Hyper*ventilation or *Hypoventilation*










Ventilation

- Normally matched with CO₂ production
- Mismatch of ventilation and CO₂ production results in hyperventilation or hypoventilation
- PaCO₂ changes quickly during mismatch
- Hyperventilation results when there is an abnormal stimulus to breathe, e.g. acidemia, hypoxia, salicylate toxicity, head injury, panic attack, pregnancy
- Hypoventilation results when the patient cannot ventilate sufficiently to keep up with CO₂ production - when severe this becomes Ventilatory Failure









Causes of Hypoxia (low PaO₂)

Low alveolar PAO₂

- Hypoventilation (\downarrow in PaO₂ $\approx \uparrow$ in PaCO₂)
- Low inspired air PiO₂ (high altitude; poor air supply)
- Responds well to oxygen Rx

Ventilation/Perfusion mismatch


- most common cause of hypoxia in lung diseases
- Responds well to oxygen Rx

Decreased rate of gas diffusion

- hypoxia worse during exertion than at rest
- Responds to oxygen Rx

Venous- Arterial shunt

- Anatomic (septal defect; patent ductus arteriosus; patent foramen ovale- PFO)
- Physiologic (collapsed or fluid-filled alveoli)
- Does not respond to oxygen Rx



Oxygen Supplement



Nasal Cannula



Mask

BMJ 1998;317:798

Acid-Base Assessment using the CO2/HCO3⁻ Buffer System

 $CO_2 + H_2O \iff H_2CO_3 \iff H^+ + HCO_3^$ pH = 6.1 + log ([HCO_3^] / [CO_2 + H_2CO_3])

- CO₂: the conjugate acid; regulated by ventilation; called the "respiratory component"
- HCO3⁻: the conjugate base; regulated by kidneys; called the "metabolic component"
- Base Excess: mEq/L titration of blood with acid (+) or base (-) to pH 7.40; a more precise & quantitative measure of the metabolic component

Acid-Base Imbalance

Metabolic Acidosis

- BE and HCO^{3⁻} less than normal Metabolic Alkalosis
- BE and HCO3⁻ above normal
- **Respiratory Acidosis**
- PaCO₂ above normal (hypoventilation)
 Respiratory Alkalosis
- PaCO₂ less than normal (hyperventilation)


Clinical Assessment of Arterial Blood Gases

- Step 1: evaluate Ventilation (also the Respiratory Component of acid-base status), using PaCO₂
- Step 2: evaluate Oxygenation, using PaO₂ (note if oxygen supplement is being used)
- Step 3: evaluate pH
- Step 4: evaluate the *Metabolic Component* of acid-base status (BE, HCO₃)

Basic Pulmonary Function Tests


- Measurements of lung and expired air volumes, airflow rates, and alveolar gas diffusion
- Range of technology: simple (peak flow, spirometry) to advanced (TLC, DLco)
- Results reported both as measured values and as % predicted for the person's age, size, sex and race

$$\mathsf{V}_{\mathsf{T}\mathsf{G}} = \frac{\Delta\mathsf{V}}{\Delta\mathsf{P}\mathsf{A}} \cdot (\mathsf{P}_{\mathsf{I}} + \Delta\mathsf{P}\mathsf{A})$$



Boyle's Law Method for Lung Volume Measurements


SUMMARY CURVES FOR PREDICTING NORMAL VALUES IN CHILDREN




"Predicted" values for pulmonary function tests are the expected average values for individuals with normal lungs, adjusted for body size, sex, age and race

In addition, values for the upper or lower limits of normal may be reported along with the predicted values


Lung Volumes in Lung Disease




Lung Volumes



Spirometry: Detection of Airway Obstruction



Causes of Changes in FEV1



Example: a healthy 22 year old male

Lung Volumes

- TLC 6.0 L
- VC 4.8 L
- RV 1.2 L (20% of TLC)

Spirometry

- FVC 4.8 L
- FEV1 4.0 L
- FEV1/FVC 0.83
- PEF 10.0 L/s (600 L/min)

Diffusing Capacity (DLco)

- Measurement of diffusion rate of carbon monoxide across the alveolar-capillary membranes
- DLco is reduced in pulmonary fibrosis (reduced rate of gas diffusion), emphysema (reduced alveolar surface area), and any other disease that results in loss of alveolar numbers or function (pulmonary edema, pneumonia, surgical removal, etc.)
- DLco is useful for monitoring patients that are taking drugs with potential pulmonary toxicity, to detect early changes that may still be reversible

Patterns of PFT Abnormalities

<u>Test</u>	Restrictive Disease <u>(e.g. Pulm. Fibrosis)</u>	Obstructive Dis <u>Asthma</u>	ease <u>COPD</u>
TLC	Decreased	Normal to Increased	Increased
RV	Decreased (%TLC normal)	Normal to Increased	Increased
FVC	Decreased	Normal to Decreased	Decreased
FEV ₁	Decreased	Decreased	Decreased
FEV ₁ /FVC	Normal	Decreased	Decreased
PEF	Decreased	Decreased	Decreased
DLco	Decreased (fibrosis)	Normal	Decreased

Exhaled Nitric Oxide (eNO)

- NO a relatively stable free radical gas
 - Generated from arginine by NO synthases (NOS)
 - Numerous physiological functions
 - Most airway cells (resident and inflammatory) can express NOS, and NOS may be induced in epithelial cells during inflammation
- Some of the NO generated by airway cells is carried in exhaled air, and elevated eNO may be an indicator of inflammation in the airways

How Can We Use eNO?

- Asthmatics with [↑]eNO may be more likely to improve with antiinflammative Rx
 - possible use to guide choice of controller Rx
- eNO usually decreases with inhaled steroid Rx
 - Indicator that pt is using the Rx
 - Guide for tapering steroid to lowest effective dose
- Caveats- eNO also is *reduced* by some inflammatory processes that increase conversion of NO to nonvolatile stable nitrates, by ↓ airway pH, & by exposure to tobacco smoke
- eNO has been approved by FDA for assessing asthma, but has not yet found a clear role in asthma diagnosis & treatment

2011 Practice Guidelines for eNO Use in Asthma

American Thoracic Society Documents

TABLE 5. GENERAL OUTLINE FOR FENO INTERPRETATION: SYMPTOMS REFER TO COUGH AND/OR WHEEZE AND/OR SHORTNESS OF BREATH*

	$F_{E_{NO}} < 25ppb$ (<20 ppb in children)	FENO 25–50 ppb (20–35 ppb in children)	$F_{E_{NO}} > 50 \text{ ppb}$ (>35 ppb in children)
		Diagnosis	
Symptoms present during past 6+ wk	Eosinophilic airway inflammation unlikely Alternative diagnoses Unlikely to benefit from ICS	Be cautious Evaluate clinical context Monitor change in FE _{NO} over time	Eosinophilic airway inflammation present Likely to benefit from ICS
	Monitoring (in Pa	itients with Diagnosed Asthma)	
Symptoms present	Possible alternative diagnoses Unlikely to benefit from increase in ICS	Persistent allergen exposure Inadequate ICS dose Poor adherence Steroid resistance	Persistent allergen exposure Poor adherence or inhaler technique Inadequate ICS dose Risk for exacerbation
Symptoms absent	Adequate ICS dose Good adherence ICS taper	Adequate ICS dosing Good adherence Monitor change in FENO	Steroid resistance ICS withdrawal or dose reduction may result in relapse Poor adherence or inhaler technique


Definition of abbreviations: FENO = fraction of exhaled nitric oxide; ICS = inhaled corticosteroid.


*The interpretation of FENO is an adjunct measure to history, physical exam, and lung function assessment. See text and Tables 3 and 4 for other details.

Am J Respir Crit Care Med 2011; 184:602.

609

Reversibility with Bronchodilation in Asthma





Assessing Exercise Tolerance

- COPD or Pulmonary Fibrosis- ability to perform physical activities
 - 6 minute walk
 - Record total distance covered in 6 minutes
 - Monitor SpO₂ for desaturation during exercise
 - Symptom scale for dyspnea & leg fatigue
- Asthma- airway obstruction associated with exercise
 - Document changes in PEF or FEV₁ with exercise
 - Standardized test using treadmill and dry air

pH 7.39, PaCO2 53, PaO2 55, HCO3 31, BE +5.0

Ventilation Hypoventilation

Oxygenation Decreased

pH Normal range

Metabolic Component Increased

Acid-Base Status Resp. acidosis + met. alkalosis

Clinical problem Chronic bronchitis and emphysema

pH 7.49, PaCO2 30, PaO2 100, HCO3 23, BE 1.2

Ventilation Hyperventilation

Oxygenation Normal to increased

pH Alkalemia

Metabolic Component Normal

Acid-Base Status *Respiratory alkalosis*

Clinical problem Acute psychogenic hyperventilation

pH 7.45, PaCO2 33, PaO2 64, HCO3 24, BE 1.1

Ventilation Hyperventilation

Oxygenation Decreased

pH Alkalemia

Metabolic Component Normal

Acid-Base Status *Respiratory alkalosis*

Clinical problem Acute asthma exacerbation

Ú

pH 7.32, PaCO2 51, PaO2 59, HCO3 27, BE 0.5

Ventilation Hypoventilation

Oxygenation Decreased

pH Acidemia

Metabolic Component Normal

Acid-Base Status Respiratory acidosis

Clinical problem Acute pulmonary failure (ARDS)

pH 7.25, PaCO2 53, PaO2 80, HCO3 27, BE 0.5

Ventilation Hypoventilation

Oxygenation Low end of normal range

pH Acidemia

Metabolic Component Normal

Acid-Base Status Respiratory acidosis

Clinical problem *Drug overdose-induced coma*

pH 7.39, PaCO2 40, PaO2 187, HCO3 25, BE 0.9

Ventilation Normal

Oxygenation Increased

pH Normal

Metabolic Component Normal

Acid-Base Status Normal

Clinical problem Uncomplicated postop on oxygen supplement

pH 7.58, PaCO2 36, PaO2 108, HCO3 33, BE 11

Ventilation Normal

Oxygenation Increased

pH Alkalemia

Metabolic Component Increased

Acid-Base Status *Metabolic alkalosis*

Clinical problem Post-bicarbonate Rx; on oxygen supplement

pH 7.00, PaCO2 13, PaO2 131, HCO3 2, BE -29

Ventilation Hyperventilation

Oxygenation Increased

pH Acidemia

Metabolic Component Decreased

Acid-Base Status *Metabolic acidosis* + *resp. alkalosis*

Clinical problem Diabetic ketoacidosis; on oxygen supplement

pH 7.15, PaCO2 49, PaO2 53, HCO3 17, BE -12

Ventilation Hypoventilation

Oxygenation Decreased

pH Acidemia

Metabolic Component Decreased

Acid-Base Status Combined resp. & met. acidosis

Clinical problem Severe pneumonia and septic shock with lactic acidosis

pH 7.52, PaCO2 45, PaO2 83, HCO3 39, BE +15

Ventilation Normal range (almost hypo-)

Oxygenation Normal range (low end)

pH Alkalemia

Metabolic Component Increased

Acid-Base Status *Metabolic alkalosis*

Clinical problem Vomiting repeatedly for several days

pH 7.55, PaCO2 12, PaO2 30, HCO3 11, BE -6

Ventilation Hyperventilation

Oxygenation Hypoxia

pH Alkalemia

Metabolic Component Decreased

Acid-Base Status *Metabolic acidosis + respiratory alkalosis*

Clinical problem Healthy climber on Mt. Everest